Equities
Health CareMedical Equipment and Services
  • Price (USD)25.31
  • Today's Change0.270 / 1.08%
  • Shares traded769.12k
  • 1 Year change-1.44%
  • Beta0.8464
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in USD (TTM)5.64bn
  • Net income in USD305.00m
  • Incorporated1937
  • Employees18.00k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lantheus Holdings Inc1.50bn427.61m6.07bn834.0014.515.1512.394.066.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m6.12bn6.95k51.454.6228.114.622.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Glaukos Corp360.35m-149.57m7.77bn907.00--11.61--21.55-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Repligen Corp622.64m-17.13m7.94bn1.78k--3.94154.7212.75-0.3079-0.307911.0936.000.2331.575.29349,206.40-0.64114.38-0.70325.0350.3755.43-2.7515.918.76--0.20550.00-20.3126.91-77.6420.1324.99--
Bruker Corp3.24bn304.90m8.52bn9.71k27.114.7218.052.632.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.85bn14.50k37.801.9817.532.935.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Masimo Corp2.04bn78.60m9.05bn3.80k116.326.1852.254.431.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Bio Rad Laboratories Inc2.58bn-778.69m9.16bn8.03k--1.22--3.55-27.32-27.3290.77267.460.22941.495.61321,321.20-6.929.08-7.269.6054.4355.55-30.1841.974.520.26120.13830.00-4.673.1382.43--3.83--
Henry Schein, Inc.12.50bn314.00m9.20bn25.00k30.212.6415.540.73592.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Penumbra Inc1.16bn34.55m9.23bn4.20k279.568.35151.567.930.86020.860229.7128.780.78971.046.08277,089.502.342.322.612.6165.7063.902.973.173.25--0.02180.0024.9518.934,643.1668.609.64--
Smith & Nephew plc (ADR)5.64bn305.00m10.80bn18.00k35.852.1011.201.910.69850.698512.9211.910.55350.71284.30305,766.302.994.103.624.9969.0471.275.418.021.115.480.412579.596.402.5017.94-16.884.24--
Solventum Corp8.22bn720.00m12.03bn22.01k16.723.779.511.464.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Globus Medical Inc2.48bn91.51m13.47bn5.00k127.952.8438.505.430.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.52bn11.50k53.041.7119.694.972.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m13.86bn14.50k44.812.5019.392.030.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Data as of Nov 22 2024. Currency figures normalised to Smith & Nephew PLC's reporting currency: US Dollar USD

Institutional shareholders

4.19%Per cent of shares held by top holders
HolderShares% Held
Fiduciary Management, Inc.as of 30 Sep 20244.23m0.97%
Barrow, Hanley, Mewhinney & Strauss LLCas of 30 Sep 20243.95m0.90%
Scharf Investments LLCas of 30 Sep 20242.90m0.66%
Goldman Sachs Internationalas of 30 Sep 20241.44m0.33%
River Road Asset Management LLCas of 30 Sep 20241.24m0.28%
Brandes Investment Partners LPas of 30 Sep 20241.22m0.28%
Parametric Portfolio Associates LLCas of 30 Sep 20241.12m0.26%
Goldman Sachs Asset Management LPas of 30 Sep 2024999.19k0.23%
The Clark Estates, Inc.as of 30 Sep 2024685.00k0.16%
DePrince, Race & Zollo, Inc.as of 30 Sep 2024546.68k0.13%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.